Agree on both your points - there is a small signal, probably not clinically significant but could be disease modifying. I'm thinking: if the effect correlates with the biomarkers, it would be worth trying another trial perhaps in prodromal AD patients and negotiate with the FDA on using these biomarkers along with cognitive measure as efficacy endpoints.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.